Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implicatior

DOI: 10.1002/cmmi.146
Contrast Media and Molecular Imaging, 2007, 2, 199-205.

#	Paper	IF	Citations
153	Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. **2008**, 21, 469-90		280
152	Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. **2008**, 37, 457-64		26
151	Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. **2008**, 10, 195-204		23
150	Dynamic changes in murine vessel geometry assessed by high-resolution magnetic resonance angiography: a 9.4T study. *Journal of Magnetic Resonance Imaging*, **2008**, 28, 637-45	5.6	26
149	MRI of the basement membrane using charged nanoparticles as contrast agents. **2008**, 60, 564-74		78
148	SIMS imaging of gadolinium isotopes in tissue from Nephrogenic Systemic Fibrosis patients: Release of free Gd from magnetic resonance imaging (MRI) contrast agents. **2008**, 255, 1181-1184		20
147	Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. **2008**, 248, 77-88		120
146	Nephrogenic systemic fibrosis: early recognition and treatment. **2008**, 21, 123-8		52
145	Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?. **2008**, 21, 129-34		51
144	Gadolinium exposure in organ donors may cause nephrogenic system fibrosis in transplant recipients never exposed to gadolinium. **2008**, 8, 1075; author reply 1076		0
143	Contrast-enhanced cardiac MRI in myocardial infarction. **2008**, 17, 290-8		7
142	Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. **2008**, 59, 356-8		16
141	Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy. **2008**, 51, 677-83		59
140	Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. **2008**, 66, 200-7		80
139	An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. **2008**, 66, 187-90		34
138	Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. **2008**, 66, 230-4		236
137	Practical body MRI-A paediatric perspective. **2008**, 68, 299-308		18

136	Potential of MR-imaging in the paediatric abdomen. **2008**, 68, 235-44		21
135	Gadofullerene MRI contrast agents. **2008**, 3, 201-13		192
134	Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. **2008**, 3, 968-75		64
133	MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. **2008**, 191, 1129-39		168
132	Nephrogenic systemic fibrosis and gadolinium: a perfect storm. **2008**, 191, 1150-3		19
131	Re: chemical structure and stability of gadolinium chelates. **2009**, 29, 2099		0
130	High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. **2009**, 192, 1538-43		27
129	Lanthanum deposition in a dialysis patient. **2009**, 24, 3247-50		30
128	Technologies for localization and diagnosis of prostate cancer. **2009**, 33, 585-603		15
127	Nephrogenic Systemic Fibrosis: Clinical Review and Education for Nurse Practitioners. **2009**, 5, 344-349		4
126	Equilibrium and kinetic properties of the lanthanoids(III) and various divalent metal complexes of the heptadentate ligand AAZTA. **2009**, 15, 1696-705		83
125	Role of thermodynamic and kinetic parameters in gadolinium chelate stability. *Journal of Magnetic Resonance Imaging*, **2009**, 30, 1249-58	5.6	135
124	Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. *Journal of Magnetic Resonance Imaging*, **2009**, 30, 1259-67	5.6	381
123	Risk factors for NSF: a literature review. *Journal of Magnetic Resonance Imaging*, **2009**, 30, 1298-308	5.6	100
122	Nephrogenic systemic fibrosis: clinical spectrum of disease. *Journal of Magnetic Resonance Imaging*, **2009**, 30, 1289-97	5.6	23
121	Nephrogenic systemic fibrosis in liver disease: a systematic review. *Journal of Magnetic Resonance Imaging*, **2009**, 30, 1313-22	5.6	23
120	Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. **2009**, 60, 1508-18		67
119	Imaging recommendations in paediatric uroradiology. Minutes of the ESPR uroradiology task force session on childhood obstructive uropathy, high-grade fetal hydronephrosis, childhood haematuria, and urolithiasis in childhood. ESPR Annual Congress, Edinburgh, UK, June 2008. **2009**, 39, 891-8		89

118	Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: a versatile and evolving technology. **2009**, 1, 583-609		129
117	Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. **2009**, 36, 1244-54		65
116	Incorporation of excess gadolinium into human bone from medical contrast agents. **2009**, 1, 479-88		192
115	Nephrogenic systemic fibrosis: histology and gadolinium detection. **2009**, 47, 841-53, vi-vii		17
114	Radiological contrast agents. **2010**, 843-864		
113	Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents. **2010**, 20, 595-603		13
112	The fate of Gd and chelate following intravenous injection of gadodiamide in rats. **2010**, 20, 1636-43		14
111	Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells. **2010**, 15, 547-57		24
110	Reduction/Dissolution of a -MnOOH Nanophase in the Ferritin Cavity To Yield a Highly Sensitive, Biologically Compatible Magnetic Resonance Imaging Agent. *Angewandte Chemie*, **2010**, 122, 622-625	3.6	2
109	Reduction/dissolution of a beta-MnOOH nanophase in the ferritin cavity to yield a highly sensitive, biologically compatible magnetic resonance imaging agent. *Angewandte Chemie - International Edition*, **2010**, 49, 612-5	16.4	32
108	Comparison of MRI properties between derivatized DTPA and DOTA gadolinium-dendrimer conjugates. **2010**, 18, 5925-31		49
107	Cardiovascular Magnetic Resonance Contrast Agents. **2010**, 76-90		3
106	NF activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. **2010**, 69, 2024-33		35
105	Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. **2010**, 69, 2017-23		32
104	Zinc transmetallation and gadolinium retention after MR imaging: case report. *Radiology*, **2010**, 257, 670-3	20.5	31
103	Poly(amidoamine) dendrimer based MRI contrast agents exhibiting enhanced relaxivities derived via metal preligation techniques. **2010**, 21, 1014-7		52
102	Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?. **2010**, 62, 337-42		11
101	Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. **2010**, 62, 38-44		32

100	MRI safety: nephrogenic systemic fibrosis and other risks. **2010**, 17, 1097-104		37
99	Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. **2011**, 4, 1206-16		77
98	Lanthanide complexes as imaging agents anchored on nano-sized particles of boehmite. *Dalton Transactions*, **2011**, 40, 6451-7	4.3	13
97	Synthesis and evaluation of nanoglobular macrocyclic Mn(II) chelate conjugates as non-gadolinium(III) MRI contrast agents. **2011**, 22, 931-7		57
96	Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. **2011**, 64, 91-6		49
95	Accumulation of rare earth elements in human bone within the lifespan. **2011**, 3, 186-94		96
94	Anthropogenic gadolinium as a microcontaminant in tap water used as drinking water in urban areas and megacities. **2011**, 26, 1877-1885		130
93	Magnetic Resonance Imaging and Angiography. **2011**, 195-208		
92	What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis?. **2011**, 24, 373-4		3
91	The role of phosphate on Omniscan( ) dechelation: an in vitro relaxivity study at pH 7. **2011**, 24, 759-68		17
90	The feasibility of in vivo detection of gadolinium by prompt gamma neutron activation analysis following gadolinium-based contrast-enhanced MRI. **2011**, 69, 105-11		15
89	MRI contrast agents based on dysprosium or holmium. **2011**, 59, 64-82		95
88	Magnetic-Field-Dependent 1H Relaxivity Behavior of Biotin/Avidin-Based Magnetic Resonance Imaging Probes. **2012**, 77, 758-769		3
87	Dissociation kinetics of open-chain and macrocyclic gadolinium(III)-aminopolycarboxylate complexes related to magnetic resonance imaging: catalytic effect of endogenous ligands. **2012**, 18, 16426-35		81
86	Nephrogenic Systemic Fibrosis. **2012**, 137-159		1
85	An extracellular MRI polymeric contrast agent that degrades at physiological pH. **2012**, 9, 1911-8		21
84	Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. **2012**, 165, 1151-62		18
83	Nephrogenic systemic fibrosis: a case report and review on Japanese patients. **2012**, 39, 449-53		5

82	Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. **2012**, 7, 144		734
81	Covalent attachment of Mn-porphyrin onto doxorubicin-loaded poly(lactic acid) nanoparticles for potential magnetic resonance imaging and pH-sensitive drug delivery. *Acta Biomaterialia*, **2013**, 9, 9434-41	10.8	48
80	Effects of image contrast on functional MRI image registration. **2013**, 67, 163-74		15
79	MR Contrast Agent Safety in the Age of Nephrogenic Systemic Fibrosis: Update 2014. **2014**, 2, 1		
78	Practice advisory on anesthetic care for magnetic resonance imaging: an updated report by the american society of anesthesiologists task force on anesthetic care for magnetic resonance imaging. **2015**, 122, 495-520		44
77	The effect of MRI contrast agents on hepatic and splenic uptake in the rabbit during (99m) Tc-MDP bone scintigraphy. *Contrast Media and Molecular Imaging*, **2015**, 10, 438-45	3.2	
76	Luminescent lanthanide nanomaterials: an emerging tool for theranostic applications. **2015**, 10, 1477-91		30
75	Magnetic nanoparticles as potential candidates for biomedical and biological applications. **2016**, 44, 918-27		21
74	The role of equilibrium and kinetic properties in the dissociation of Gd[DTPA-bis(methylamide)] (Omniscan) at near to physiological conditions. **2015**, 21, 4789-99		34
73	A feasibility study to determine the potential of in vivo detection of gadolinium by x-ray fluorescence (XRF) following gadolinium-based contrast-enhanced MRI. **2015**, 36, N1-13		8
72	A water-soluble and water-coordinated Mn(II) complex: synthesis, characterization and phantom MRI image study. *Dalton Transactions*, **2015**, 44, 12990-4	4.3	21
71	Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. **2015**, 87, 3321-8		98
70	RGD-functionalized ultrasmall iron oxide nanoparticles for targeted T1-weighted MR imaging of gliomas. **2015**, 7, 14538-46		95
69	Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. **2015**, 65, 33-7		42
68	The gadolinium-based contrast agent Omniscan promotes in vitro fibroblast survival through in situ precipitation. **2015**, 7, 1103-10		3
67	Hyperintense Dentate Nuclei on T1-Weighted MRI: Relation to Repeat Gadolinium Administration. **2015**, 36, 1859-65		110
66	The study ofin vivox-ray fluorescence (XRF) technique for gadolinium (Gd) measurements in human bone. **2016**, 11, T08001-T08001		1
65	A phantom-based feasibility study for detection of gadolinium in bone in-vivo using X-ray fluorescence. **2016**, 112, 103-9		11

64	Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. **2016**, 29, 365-76		402
63	The design of a multifunctional dendrimer-based nanoplatform for targeted dual mode SPECT/MR imaging of tumors. **2016**, 4, 7220-7225		20
62	Photoacoustic tomography: applications for atherosclerosis imaging. **2016**, 18, 084005		7
61	Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. **2016**, 98, 113-33		70
60	Development of the application of speciation in chemistry. **2017**, 352, 401-423		33
59	Shape memory polymers with enhanced visibility for magnetic resonance- and X-ray imaging modalities. *Acta Biomaterialia*, **2017**, 54, 45-57	10.8	15
58	Biocompatible magnetite nanoparticles synthesized by one-pot reaction with a cell membrane mimetic copolymer. *Materials Science and Engineering C*, **2017**, 75, 863-871	8.3	7
57	Confirming improved detection of gadolinium in bone using in vivo XRF. **2017**, 120, 111-118		12
56	Optical and Magnetic Resonance Imaging Using Fluorous Colloidal Nanoparticles. **2017**, 18, 103-112		22
55	Mn(II) based T and T potential MRI contrast agent appended with tryptamine: Recognition moiety for A□plaques. *Journal of Inorganic Biochemistry*, **2017**, 177, 76-81	4.2	12
54	Enhanced Efficiency of C Dynamic Nuclear Polarization by Superparamagnetic Iron Oxide Nanoparticle Doping. **2017**, 121, 19505-19511		5
53	Elemental content of the placenta: A comparison between two high-risk obstetrical populations, adult women carrying multiples and adolescents carrying singletons. *Environmental Research*, **2017**, 158, 553-565	7.9	12
52	A highly stable l-alanine-based mono(aquated) Mn(ii) complex as a T-weighted MRI contrast agent. *Dalton Transactions*, **2017**, 46, 10426-10432	4.3	13
51	Zwitterionic Manganese and Gadolinium Metal-Organic Frameworks as Efficient Contrast Agents for in Vivo Magnetic Resonance Imaging. *ACS Applied Materials & Interfaces*, **2017**, 9, 41378-41386	9.5	39
50	"Wait and scan" management of patients with vestibular schwannoma and the relevance of non-contrast MRI in the follow-up. *Journal of Otology*, **2017**, 12, 174-184	1.9	14
49	Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats. *Investigative Radiology*, **2017**, 52, 255-264	10.1	36
48	□acial vascular anomalies; MRI and TRICKS-MR angiography diagnostic approach□*Egyptian Journal of Radiology and Nuclear Medicine*, **2017**, 48, 885-895	1.4	1
47	Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation. *BMC Nephrology*, **2017**, 18, 249	2.7	2

46	On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging. *Acta Biomaterialia*, **2018**, 73, 458-469	10.8	35
45	Rare earth elements in German soils - A review. *Chemosphere*, **2018**, 205, 514-523	8.4	38
44	Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy. *Chemical Society Reviews*, **2018**, 47, 1874-1900	58.5	214
43	A New Bis(aquated) High Relaxivity Mn(II) Complex as an Alternative to Gd(III)-Based MRI Contrast Agent. *Inorganic Chemistry*, **2018**, 57, 2631-2638	5.1	24
42	Analysis of metal-based contrast agents in medicine and the environment. *TrAC - Trends in Analytical Chemistry*, **2018**, 104, 135-147	14.6	16
41	Observed Deposition of Gadolinium in Bone Using a New Noninvasive in Vivo Biomedical Device: Results of a Small Pilot Feasibility Study. *Radiology*, **2018**, 287, 96-103	20.5	44
40	Interactions of Alkali and Alkaline-Earth Metals in Water-Soluble Heterometallic FeIII/M (M = Na+, K+, Ca2+)-Type Coordination Complex. *Crystal Growth and Design*, **2018**, 18, 531-539	3.5	4
39	Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. *Radiology*, **2018**, 289, 517-534	20.5	136
38	Magnetic Resonance Imaging of synovitis in knees of patients with osteoarthritis without injected contrast agents using T quantification. *Radiography*, **2018**, 24, 283-288	2	3
37	N,1,4-Tri(4-alkoxy-2-hydroxybenzyl)-DAZA: efficient one-pot synthesis and labelling with Ga for PET liver imaging in ovo. *Dalton Transactions*, **2018**, 47, 9000-9007	4.3	5
36	Evaluation of the effect of switching from a linear to a macrocyclic contrast agent on the T -weighted brain signal intensity of a child during the course of 43 contrast-enhanced MRI examinations. *Journal of Magnetic Resonance Imaging*, **2019**, 49, 608-609	5.6	1
35	A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. *Radiology*, **2019**, 292, 376-386	20.5	45
34	The gadolinium hypothesis for fibromyalgia and unexplained widespread chronic pain. *Medical Hypotheses*, **2019**, 129, 109240	3.8	2
33	Gadolinium-based contrast agents: paraoxonase 1 inhibition, studies. *Drug and Chemical Toxicology*, **2021**, 44, 508-517	2.3	41
32	Effect of Ligand Chirality and Hyperconjugation on the Thermodynamic Stability of a Tris(aquated) GdIII Complex: Synthesis, Characterization, and T1-Weighted Phantom MR Image Study. *European Journal of Inorganic Chemistry*, **2019**, 2019, 2518-2523	2.3	2
31	Gadolinium as an Emerging Microcontaminant in Water Resources: Threats and Opportunities. *Geosciences (Switzerland)*, **2019**, 9, 93	2.7	40
30	Ferritin: A Platform for MRI Contrast Agents Delivery. *Inorganics*, **2019**, 7, 33	2.9	7
29	Signal intensity increases in dentate nucleus/globus pallidus/pulvinar on unenhanced T1WI MR images after multiple examinations with gadodiamide. *Neuroradiology Journal*, **2019**, 32, 215-224	2	

28	The Critical Need for Pediatric and Juvenile Animal Research Addressing Gadolinium Retention in the Developing Body. *Investigative Radiology*, **2019**, 54, 72-75	10.1	8
27	LA-ICP-MS/MS improves limits of detection in elemental bioimaging of gadolinium deposition originating from MRI contrast agents in skin and brain tissues. *Journal of Trace Elements in Medicine and Biology*, **2019**, 51, 212-218	4.1	27
26	Chemical Insights into the Issues of Gd Retention in the Brain and Other Tissues Upon the Administration of Gd-Containing MRI Contrast Agents. *European Journal of Inorganic Chemistry*, **2019**, 2019, 137-151	2.3	21
25	Spinel ferrite nanoparticles and nanocomposites for biomedical applications and their toxicity. *Materials Science and Engineering C*, **2020**, 107, 110314	8.3	75
24	New Strategies in the Design of Paramagnetic CAs. *Contrast Media and Molecular Imaging*, **2020**, 2020, 4327479	3.2	4
23	MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis. *Magnetic Resonance Imaging Clinics of North America*, **2020**, 28, 497-507	1.6	11
22	Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 1226-1237	5.3	3
21	Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging. *Investigative Radiology*, **2020**, 55, 629-635	10.1	6
20	Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles. *Histochemistry and Cell Biology*, **2021**, 155, 19-73	2.4	1
19	A Single-Pot Template Reaction Towards a Manganese-Based T1 Contrast Agent. *Angewandte Chemie*, **2021**, 133, 10831-10839	3.6	0
18	A Single-Pot Template Reaction Towards a Manganese-Based T Contrast Agent. *Angewandte Chemie - International Edition*, **2021**, 60, 10736-10744	16.4	15
17	MR Imaging of Paediatric Abdomen. **2009**, 639-674		2
16	Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. *Indian Journal of Dermatology* , **2011**, 56, 65-73	0.9	20
15	Gadolinium Deposition in the Brain and Body. *Journal of the Belgian Society of Radiology*, **2019**, 103,	0.6	3
14	Renal Transplantation Is Associated with Improved Clinical Outcomes in Nephrogenic Systemic Fibrosis. *ISRN Transplantation*, **2013**, 2013, 1-10		1
13	A case of delayed onset nephrogenic systemic fibrosis after gadolinium based contrast injection. *Annals of Rehabilitation Medicine*, **2012**, 36, 880-6	1.7	15
12	Cutaneous Manifestations of Renal Disease. **2012**, 31-40		
11	Gadolinium. **2016**, 491-504		0

10	Introduction to Contrast-Enhanced Imaging. **2018**, 1-24		
9	Cardiovascular Magnetic Resonance Contrast Agents. **2019**, 27-39.e4		
8	Mn(II) complexes of phenylenediamine based macrocyclic ligands as T-MRI contrast agents.. *Journal of Inorganic Biochemistry*, **2021**, 228, 111684	4.2	1
7	How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo.. *Molecules*, **2021**, 27,	4.8	0
6	Magnetic Nanoparticles for Diagnostic and Therapeutic Applications. **2022**, 609-639		0
5	Comparison of different analytical methods for speciation of seven gadolinium-based magnetic resonance imaging contrast agents and the applications in wastewater and whole blood.		0
4	Automatic detection of active and inactive multiple sclerosis plaques using the Bayesian approach in susceptibility-weighted imaging. 028418512211430		0
3	QSM Throughout the Body.		0
2	Gadolinium(III) Complex-Backboned Branched Polymers as Imaging Probes for Contrast-Enhanced Magnetic Resonance Angiography. **2023**, 15, 18311-18322		0
1	Vestibular Impairment in Patients with Vestibular Schwannoma: A Journey through the Pitfalls of Current Literature. **2023**, 13, 285-303		0